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Abstract  
Background. In the past 20 years, BK virus has emerged as a cause of early graft 
dysfunction after kidney transplantation. In the setting of chronic immunosuppression 
(IS), the latent virus can reactivate, leading to BK viremia (10-20%) and in 1-10% of 
kidney transplant recipients to BK virus nephropathy (BKVN). The early detection of 
BK viremia by serum DNA PCR screening allows prompt but controlled reduction of 
IS, which, despite numerous attempts to find specific antiviral agents, remains the 
mainstay therapy. So far, besides potent IS, no risk factor has been consistently 
associated with BK viremia/BKVN. The use of a ureteral stent at the time of 
transplantation to protect the ureterovesical anastomosis has been described as a 
potential trigger. In this study, we aimed at defining the incidence and kinetics of BK 
viremia in our local cohort of kidney transplant recipients, and analysed potential 
predictors of BK viremia/BKVN, including ureteral stents. 
Methods. We performed a single-centre retrospective study on consecutive patients 
who received a kidney transplant at the CHUV between 01.11.03 and 31.12.12, with 
at least 12 months follow-up. First, descriptive statistics were done to define the 
general characteristics of the population. From a total 308 patients, a subpopulation 
of 195, transplanted between 01.01.08 and 31.12.12, had enough data for relevant 
analysis of BK viremia status during the first year as well as the use of a ureteral 
stent. Statistical analyses were performed using R-software. 
Results. BK viremia (>1000 copies/ml at least twice) was detected in 37/195 (19%) 
patients within the first year post-transplantation, with an early onset in the first 4 
months for 65%, whereas only 6 patients were newly diagnosed after 12 months. 
28/195 (14.4%) had a peak BK viremia >10’000 copies/ml, which represents a high 
positive predictive value for BKVN. Patients with BK viremia had a significantly lower 
kidney function at one year as compared to BK viremia negative recipients 
(eGFR=58 vs. 67 ml/min; p=0.019), and eGFR decreased as viremia levels 
increased, in particular >10’000 copies/ml. We found no significant association with 
the type of graft (living vs. cadaveric donor), or IS protocols (Basiliximab vs. 
Thymoglobulin induction, tacrolimus vs. cyclosporine). Interestingly, combining 
recipient’s age and gender, we observed a higher risk to reactivate BK virus in older 
men (p=0.05). Ureteral stents were placed in 76/195 patients (39%), but their use did 
not significantly influence BK viremia. 
Conclusion. Considering the incidence of BK viremia in our population (22%), the 
fact that BKVN represents a poor prognosis factor for graft function and that viremia 
detection by PCR allows early diagnosis and management, our data reinforce the 
importance of regular screening early after kidney transplantation and in the case of 
unexplained rise in serum creatinine. Based on current knowledge and on our data, a 
prospective randomized multicentre study with controlled variables (IS, ureteral 
stents) and standardized follow-up charts (including urological 
complications/manipulations) would help better understand the determinants of BK 
viremia/BKVN. 
Key words. Kidney transplantation, BK virus, Ureteral stent, Immunosuppression  
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Introduction 
1. Kidney transplantation  
At the end of June 2015, according to SwissTransplant statistics, 1050 patients were 
waiting for a kidney and registered on the waiting list. During the 2 first semesters of 
2015, 162 kidney transplantations have been performed in Switzerland, 115 thanks 
to deceased donors and 47 from living donors, sometimes preemptively (before 
starting dialysis). Considering the disproportion between the patients in need of a 
kidney and the transplantations possibilities, it is our duty to prevent any complication 
that could reduce kidney graft function in the perspective of helping the transplanted 
patient having a longer and healthier life. 
In the world of organ transplantation, the kidney plays a special role. Because of its 
relatively easy surgical removal and implantation (in comparison with other organs), 
as well as the possibility to use kidneys from living donors, it is the first organ 
transplanted successfully (1954). Before the discovery of the human leucocyte 
antigen (HLA) system (1958), a better understanding of the mechanisms of organ 
rejection as well as the availability of efficacious immunosuppressive protocols 
(Azathioprine-Prednisone in the 70’s and Cyclosporine A in the 80’s), successful 
kidney transplantations were only possible between identical twins. Progressively, 
kidney transplantations between HLA-mismatched donor-recipient pairs and 
transplantations from cadaveric donors have been successfully performed. 
Nowadays, because of the many diseases that cause end stage renal disease 
(ESRD) and despite the access to chronic dialysis, the kidney is the more needed 
organ. The fact that two kidneys are available from a cadaveric donor and that living 
donations are possible helps to maintain the balance between supply and demand in 
acceptable ranges. General consensus establishes that kidney transplantation is the 
optimal treatment for most patients with ESRD, despite the risks associated with the 
transplantation surgery and lifelong immunosuppressive therapy. This procedure 
restores a near normal kidney function and contributes to the patient’s quality of life.  
The other existing renal replacement therapies are hemodialysis and peritoneal 
dialysis. Constant improvement in the techniques and the possibilities of at-home 
dialysis render dialysis a long-lasting and life-saving therapy for ESRD patients. 
However, because of dialysis possible side effects and non-optimal blood 
purification, the life expectancy of patients on chronic dialysis is significantly shorter 
as compared to kidney-transplanted patients, mainly due to cardiovascular 
complications. 
Preemptive transplantation is defined as elective transplantation prior to the start of 
chronic dialysis and, given the long waiting lists, this procedure is generally possible 
by living-donor transplantation. Current data show that patients and grafts survival is 
longer after preemptive kidney transplantation as compared to transplantation after a 
period of chronic dialysis. Moreover, as the adverse effects of dialysis on post-
transplant outcomes are duration dependent, transplantation should ideally be 
performed as soon as possible. 
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The type of kidney donation also influences patient and graft survival. Transplants 
obtained from deceased donors often suffer from prolonged ischemia time and some 
degree of renal impairment may also result from donor’s comorbidities, older age and 
organ retrieval procedures (for example donation after cardiac death). In comparison, 
living donation allows the selection of a healthy donor for the transplantation 
procedure as well as planning of the surgery, allowing graft removal and 
transplantation under favorable conditions and shorter cold ischemic time. Thanks to 
minimal invasive surgical techniques and extensive preoperative examination, the 
removal of a kidney from a living, healthy and motivated human is acceptable. 
According to the United Network for Organ Sharing (UNOS), in 2001, kidney graft 
survival at 5 years after transplantation was 10% greater after living versus cadaveric 
donation (91% vs. 81%, respectively).  
 
2. Immunosuppressive therapy after solid organ transplantation  
Immunosuppression (IS) is an essential element to ensure optimal patient and graft 
outcome after solid organ transplantation (SOT), as it allows preventing and treating 
rejection episodes. 
The induction therapy is given at the time of transplantation and its purpose is to 
improve the efficacy of immunosuppression and reduce early acute rejection 
episodes. Indeed, the use of potent induction therapies allows delayed introduction 
as well as lower doses of calcineurin inhibitors (CNI), which are potentially 
nephrotoxic. The induction therapy aims at depleting or modulating recipient’s T-cell 
responses during donor’s antigen presentation. Basiliximab, an anti-IL-2 receptor 
alpha-chain monoclonal antibody, binds this molecule, which is upregulated at the 
surface of activated T lymphocytes and competitively inhibits IL-2-mediated effector 
functions. This modulation of T cells is reversible and Basiliximab is used in patients 
at low immunological risk of rejection (first transplantation, non-sensitized recipients). 
In high immunological risk patients (second transplantation, sensitized recipients) or 
in the case of delayed graft function (DGF), Thymoglobulin (rabbit polyclonal anti-
thymocyte globulin), a T-cell depleting agent is preferentially used. In hypersensitized 
recipients with pre-existing donor-specific antibodies (DSA), intravenous 
immunoglobulins (IvIg) can be administered together with Thymoglobulin and/or 
plasma exchanges can be performed to remove DSA. 
The maintenance therapy is the long-term treatment, which is necessary to down-
regulate the immune system against the allograft in order to prevent acute and 
chronic rejection that lead to progressive graft dysfunction. It consists of a 
combination of 2 or 3 drugs, to achieve sufficient immunosuppression while 
minimizing the toxicity and adverse effects of any single agent that if used alone 
would need higher doses to be efficacious. The Kidney Disease Improving Global 
Outcomes (KDIGO) guidelines recommend the combination of a CNI, an 
antiproliferative agent and corticosteroids. Since the risk for acute rejection is highest 
in the first 3-6 months after transplantation, higher immunosuppressive doses are 
used in this early period and then immunosuppression is carefully reduced in stable 
patients to minimize toxicity. CNI block the T-cell receptor early downstream signaling 
after interaction with the major histocompatibility complex (MHC): peptide complex 
presented on the surface of the antigen-presenting cell (APC) (signal 1, Figure 1). 
Among the CNI, Tacrolimus (FK) is currently preferentially used as compared to 
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Cyclosporine (CsA) in many transplantation programs. Anti-metabolites agents such 
as Mycophenolate mofetil (MMF), Mycophenolic acid (MPA) or Azathioprine (AZA) 
act on the cell cycle and proliferation. Prednisone is also part of initial 
immunosuppression but owing to the known adverse effects in the long term, the 
drug is progressively tapered or even stopped at 1 year in low immunological risk 
recipients. Mammalian target-of-rapamycin inhibitors (mTORi), such as Sirolimus and 
Everolimus, act on cell proliferation and are used either as replacement for CNI or 
combined with low-dose CNI to limit nephrotoxicity. 
As immunosuppressive therapy is a lifelong treatment in transplanted patients, 
research is constantly comparing the different protocols in order to propose greater 
efficacy in preventing rejection with as little as possible toxicity. 
 
 
 
 
        
 
 
 
Figure 1. Targets of immunosuppressive drugs used in transplantation.  
Adapted from Halloran PF. N Engl J Med 2004; 351; 2715. 
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3.  Surgery 
The kidney allograft is placed in the iliac fossa and the renal artery and vena are 
anastomosed on the recipient’s iliac external artery and vena. For the 
ureteroneocystostomy, the bladder is filled with NaCl and the side is opened plan by 
plan to perform the anastomosis. To rule out an eventual leakage, the bladder is 
expanded by NaCl and an “anti-reflux” stitch is done on the anastomosis (Lich-
Gregoir technique). 
The ureteral anastomosis during the kidney transplantation procedure is a common 
cause (5-9%) (1) of urinary complications such as leakage, ureteral necrosis, 
stenosis, obstruction, hematuria, vesicoureteral reflux and infections. Despite the 
improvement of urological techniques, it remains a potential cause of reoperation and 
postoperative morbidity. The use of an ureteral stent, also named double pigtail or 
double J stent, at the time of the anastomosis has be shown in a meta analysis in 
2004 (1) to reduce urological complications from 9% to 1.5%. The proposed benefits 
of the stent are the continuous decompression of the ureter to avoid anastomotic 
tension, maintenance of the ureter in a more linear alignment to avoid kinking, and 
protection from postoperative lumen obstruction due to edema or external 
compression. Some transplantation centers use the ureteral stent on a routine basis 
(Geneva, Zurich, Bern), whereas some others use it selectively according to the 
transplant-surgeon’s decision. A small bladder, previous urological operations, 
double, fine or injured ureters are some reported causes of selective stent placement 
at the time of the transplantation. Ureteral stents are also used to repair a leakage or 
a stenosis in the first months after transplantation. There is no consensus regarding 
the ideal time-interval between the stent placement and ablation. Most of the stents 
are removed between 1 and 12 weeks after transplantation, once the anastomosis is 
thought to have healed. Some studies have reported that reducing the stenting time 
can reduce the complications of the prolonged use of the stent without compromising 
the benefit. Indeed, the ureteral stent is rapidly covered with a bacterial biofilm when 
in contact with urine, which can lead to urinary tract infections in 
immunocompromised kidney transplant recipients. Other complications are migration 
of the stent, irritation of the bladder resulting in pain, hematuria, stones incrustation 
and fibrosis of forgotten stents making the removal difficult and at risk of injury. The 
placement of a stent leads to the need of a postoperative procedure for stent removal 
by cystoscopy. Another potential complication of ureteral stents is the reported 
increased risk of BK viremia and BK nephropathy (2)(3)(4)(5) in kidney transplant 
recipients. 
 
4. BK virus 
Historic: The BK virus has been first isolated by Gardner et al. in 1971 from the urine 
of a renal allograft recipient with ureteric obstruction and named after this patient (6). 
In 1995, Purighalla et al. described kidney biopsies of a transplanted man who 
underwent two reversible episodes of acute rejections and presented thereafter 
another episode of allograft dysfunction (7). At that time, the kidney biopsy showed a 
combination of rejection and viral infection with mixed inflammatory interstitial 
infiltrates, focal tubulitis and enlarged basophilic nuclei of the tubular epithelial cells 
which reacted with an anti-Simian virus (SV40). Partial clinical response was 
obtained with steroid treatment and 7-days IvIg treatment. Their attempt to lower 
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immunosuppression to eradicate the BK viral infection resulted in graft loss. This first 
description of BKV nephropathy illustrated the 2 main problems of BK infection: the 
diagnosis was difficult to set as graft dysfunction was first considered as a rejection 
episode and treated accordingly with increased immunosuppression which lowered 
the chance to clear the virus. The second challenge was the treatment of BKV 
nephropathy (BKVN) after diagnosis, which is still nowadays relevant. Indeed, 
despite numerous attempts, no specific treatment has been found and the reduction 
of immunosuppression remains the best option, with however a significant risk of 
graft rejection.  
In the past 20 years, the increasing awareness of BK virus in kidney transplant 
recipients may be in part explained by the earlier detection of the virus in plasma and 
the apparition of potent immunosuppressive drugs (Tacrolimus and MMF in 1994 and 
1995, respectively). Currently, the prevalence of BK viremia reaches about 10-20% 
(8)(9) at 1 year post transplantation. The prevalence of BKVN confirmed by kidney 
biopsy was reported to be about 1-10% of kidney transplant recipients (5)(10)(11) in 
2009 with different prevalences according to the centers, most likely reflecting the 
variable local immunosuppression protocols and diagnostic approaches. 
At the end of the 1990’s, BKVN lead in 30 to 60% of the cases to irreversible kidney 
graft failure (12). Since about 10 years, the earlier detection of BK viremia and the 
prompt adaptation of immunosuppression have resulted in the reduction of the 
incidence of BKVN and kidney graft lost. 
 
Characteristics of BK virus: BK virus is a circular, double-stranded DNA virus from 
the polyomavirus family that also includes SV40 and JC virus. The genome encodes 
3 viral capsid protein (VP1, 2 and 3) and large-T and small-t antigens, which are 
recognized by our cellular immunity. The BK virus has been divided into 6 genotypes 
and further subgroups with a specific geographical distribution pattern (13).  
 
Pathogenesis of BKV infection: Exposure to BK virus occurs mostly in childhood 
as seropositivity reaches 80-90% in young adults around the world and seems not to 
have changed since the first discovery of the virus in the 1970s. The virus, which 
infects the urothelial epithelium and renal tubular epithelial cells, remains latent and 
asymptomatic in immunocompetent adults, although 5-10% present intermittent 
reactivation and low-level viruria (3)(11). In the state of immunosuppression, such as 
after kidney transplantation, HIV infection or pregnancy, BK virus can reactivate and 
replicate, causing renal tubular cell lysis with shedding of virus into the urine 
(viruria). About 30% (9) of kidney transplant recipients were described to present 
viruria, detected by DNA PCR or by the presence of so called “decoy cells” in the 
urine. These cells with viral inclusions, stained by the Papanicolaou method in 
cytology, are the sign of BK virus replication in the urinary tract but are not a specific 
marker of BKV nephropathy. In about 1/3 of the patients with viruria, the BK virus can 
multiply in the renal interstitium and cross into the peritubular capillaries, causing 
viremia. The presence of BK virus in patient’s plasma is detected by DNA PCR, 
which has become in recent years a widely used method for the early detection of BK 
virus replication. In some permissive situations, the virus invades the renal allograft, 
leading to tubulointerstitial lesions, inflammation and interstitial fibrosis. 
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Polyomavirus-associated (PVAN) or BK virus nephropathy (BKVN) occurs without 
specific clinical signs or symptoms, except for the increase of serum creatinine 
concurrent with increasing BK viremia titers. Kidney transplant biopsy remains the 
gold standard for the diagnosis of BKVN with specific histological modifications on 
hematoxylin-eosin and after immunohistochemical staining using the anti-SV40 
antibody (cross-reacting with BK). Graft biopsies also help to rule out other potential 
complications underlying kidney dysfunction, such as cellular or antibody-mediated 
rejection. Thus, early detection of low level BK viremia in the context of screening 
protocols or of rising plasma creatinine, as well as prompt reduction of IS would help 
to prevent long-term damage of the graft and avoid some of the kidney biopsies.  
Besides kidney transplantation, BK virus is known to cause hemorrhagic cystitis and 
BKVN in highly immunosuppressed bone marrow transplant recipients. Some 
isolated cases of BK viruria and viremia have been recently described in other SOT 
recipients (heart, lungs, liver). For example, some cases of BKVN occurring in the 
native kidneys of heart transplant recipients have been reported (14), showing that 
BK virus infection may enter in the differential diagnosis of worsening kidney function 
in SOT recipients other than kidneys. The much higher prevalence of BKVN in kidney 
transplant recipients has be explained by the potentiating role of alloimmune 
activation in the kidney graft depending on the degree of donor-recipient HLA 
mismatches (12). Indeed, BKVN is described to develop in the context of IS (first hit) 
on a predisposed ground (second hit), such as chemical or mechanical insult of the 
urothelium resulting in local inflammation. Ischemia-reperfusion injuries at the time of 
transplantation, prior rejection episodes or the presence of stents or catheters in the 
urinary tract may provide a suitable environment for the replication of BK virus.   
 
Cellular immune responses to BK: Recipient’s T cells recognize antigens (large-T 
antigen and VP1 capside protein) on the BK virus and become effector cells by 
secreting IFN-γ, which helps to clear the infection. Schematically, a lower number of 
BK-specific IFN-γ-secreting T lymphocytes has been reported in patients with BKVN 
and the reduction of IS was followed by an increase of the IFN-γ activity and the 
resolution of BKVN. Ineffective immune surveillance by host’s T lymphocytes has 
been proposed as one of the potent factors that contributes to the pathogenesis of 
BKVN (12).  
 
Humoral immunity to BK: As opposed to cytomegalovirus (CMV) virus, pre-
transplantation screening for donor/recipient BK serostatus is not a routine procedure 
in the clinic. However, humoral immunity may play a role in the pathogenesis of 
BKVN since a donor seropositive and recipient seronegative status (D+/R-) has been 
reported as a potential risk factor.  
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BK virus in kidney transplantation: So far, aside from potent IS therapy, no 
association has been consistently identified as a risk factor for BK viremia and/or 
nephropathy. This may suggest that several factors contribute to BK virus 
reactivation and are likely to interact with one another. In the context of highly 
immunosuppressed patients at risk of graft dysfunction or loss, the detection of 
multiple risk factors may help to identify patients with higher risk of BK reactivation in 
order to prevent BKVN. 
Potential risk factors for BK viremia and nephropathy. Adapted from Suwelack et al. (15) 
Immunosuppression Other risk factors 
Induction Donor factors 
Thymoglobulin: increased risk of BK 
infection, higher rate of BK replication 
High degree of HLA mismatches, 
alloimmune activation (stronger IS) (9)  
BK serostatus mismatch: D+R-  
Basiliximab: does not appear to affect the 
risk of BK infection 
Prolonged ischemic time, immunological 
injury, delayed graft function 
Maintenance  Recipient factors 
CNI Older age 
CsA: in vitro suppression of BK replication  
Introduction in the mid 80’s: no rise of 
BKVN 
Male gender 
Previous graft loss (stronger IS, 
Thymoglobulin) 
FK: the most potent inhibitor of BKV-
specific T cells, increased risk of BKVN 
Retransplantation after graft loss due to 
BKVN 
Pediatric status (seronegative recipient) 
Anti-metabolites Surgical/medical factors 
MMF: uncertain effect Ureteral stent (routine or selective use) 
FK-MMF combination: appears to create a 
permissive environment for BK replication 
(15) Other catheters in the urinary tract 
Corticosteroids Viral factors 
i.v. Pulses: significant association with BK 
replication and BKVN (9) Capside serotype, caveolin scaffolding 
FK-MMF-Prednisone: has been 
demonstrated prospectively as a greater 
risk for BK replication and BKVN (8) 
Rearrangement of viral control regions 
Replicative fitness 
 
Treatment of BKVN: The aim of the treatment is to clear BK virus to protect kidney 
function, while avoiding acute and chronic rejection. In the absence of proven 
polyomavirus-specific antiviral agents, the mainstay of BK viremia/nephropathy 
treatment remains the reduction of IS. Cidofovir is an antiviral agent that inhibits viral 
DNA synthesis, but it has nephrotoxic side effects. Leflunomide and its derivative 
FK778 are pyrimidine synthesis inhibitors that are efficient for the treatment of BKVN 
but increase the risk of acute rejection and do not appear to present more benefits 
than IS reduction alone. Ciprofloxacin has also been described (instead of co-
trimoxazole prophylaxis) but this may increase the risk of pathogens resistance and 
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there is no clear proven duration of treatment. According to the current KDIGO 
guidelines (16), there is no definitive data confirming the effectiveness of any of these 
agents for either treating or preventing BKVN. 
How IS has to be reduced is not yet clearly proven. The actual propositions of 
treatment are the followings: -­‐ switch from MMF to AZA, or reduction followed by discontinuation of MMF -­‐ switch from FK to CsA, or 25-50% reduction of the CNI dose  -­‐ switch to an mTORi-prednisone protocol 
The use of IvIg in parallel to IS reduction has shown good results but the efficacy of 
IvIg alone is not known. Independently of the reduction of IS, careful monitoring of 
kidney function and BK viremia by DNA PCR are essential. In their paper, Dall and 
Hariharan (12) propose a control every 2 weeks during 8 weeks then every month 
until the clearance of BK viremia and the stabilization of kidney function. 
 
Possibility of retransplantation after BKVN: The retransplantation of patients who 
have lost their kidney graft due to BKVN appears to be possible (17). It seems that 
there is no need for BK viremia negativation or nephrectomy of the infected graft 
before undergoing a second transplantation. However, a relative low rate of BK virus 
replication is recommended before retransplantation, as well as close monitoring of 
BK viremia and kidney function to detect possible recurrence under IS. In our center, 
a few patients have been retransplanted after the loss of their kidney graft due to 
BKVN. At the time of retransplantation, BK viremia was <1000 copies/ml and did not 
increase during the follow-up. 
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Aims  
The aims of this study were  
• to update the database of the CHUV kidney transplant recipients cohort in 
order to study this population.  
• to define the incidence and predictive factors of BK viremia during the first 
year after transplantation in the CHUV kidney transplant recipients cohort.  
• to study the association between the exposure to an ureteral stent at the time 
of transplantation and BK viremia during the first year after transplantation. 
 
Material and methods 
This study analyses retrospectively the clinical data of 330 adult patients who 
underwent kidney transplantation at the Centre Hospitalier Universitaire Vaudois 
(CHUV) between November 2003 and December 2012. All patients have had at least 
one year follow-up at the Centre de Transplantation d’Organes (CTO) and patients 
under 20 years of age were excluded because they were followed by paediatricians.  
The study is based on data collected on medical paper files and follow-up charts 
available at CTO and completed by documents archived on electronic centralized 
files of the CHUV (Archimède). Part of these data have been gathered by Jeremy 
Jankovic and Mathias Stevanin as part of their Master projects.  
The BK viremia results, provided by Professor P. Meylan, as well as the operative 
protocols, provided by Dr M. Matter, have been analysed and classified for each 
patient.  
 
The database contains the following parameters:  -­‐ Baseline recipient’s clinical data at the time of transplantation: age, gender, 
number and type of previous grafts, pre-transplantation kidney disease.  -­‐ Type of graft: living vs. deceased donor, transplantation procedure (cold 
ischemia time). -­‐ Induction and maintenance immunosuppression.  -­‐ Clinical follow-up at one year: patient’s weight and kidney function. -­‐ BK viremia analysis: first significant positive value (>1’000 copies), peak value, 
date of viremia negativation (<1’000 copies), kidney biopsy results when 
available. -­‐ Operative protocols: reason and use of an ureteral stent, date and reason for 
the ablation of the stent.  
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Diagram 1. Selection of patients  
	  
As depicted in Diagram 1, from the 330 consecutive kidney transplantations 
performed at the CHUV between November 2003 and December 2012, 14 (4,2%) 
patients were explanted or died with a functioning graft in the first year after 
transplantation. Eight patients have also been excluded from the study due to no 
follow-up at one year. The first description of the population in this study has been 
made on 308 patients, to give a general view of the kidney transplant recipients 
routinely followed at the CHUV. 
As we needed a regular screening for BK viremia and the use of ureteral stent, 
patients transplanted before 01.01.2008 have been excluded from the detailed 
statistical analysis. Indeed, either BK viremia screening was inconsistent or the 
surgeon’s use of ureteral stents very occasional before this date. A further 3 patients 
have been excluded because of no known date of ureteral stent removal. The 
detailed statistical analysis is finally based on 195 adult patients with at least one 
year follow-up, including regular BK viremia screening and the possible use of an 
ureteral stent according to operative findings and surgeon’s preference. 
 
Immunosuppression protocol: The induction therapy prescribed at the CHUV was 
based on Basiliximab and/or Thymoglobulin according to the immunological risk of 
the recipient. Maintenance therapy generally consisted of the combination of a CNI 
(FK or CsA), an anti-metabolite (MMF/MPA or AZA) and Prednisone (P). At the 
CHUV, the standard maintenance immunosuppressive protocol was based on FK, 
MMF and Prednisone during the first year after transplantation. The CNI doses were 
adjusted according to therapeutic drug monitoring (TDM), anti-metabolites according 
to digestive and haematological tolerability, and prednisone following a tapering 
protocol during the first year. 
!!!!!!!!!!!!!!!!!!!
330!adults!patients!transplanted!in!the!CHUV!between!November!2003!and!December!2012!
308!patients!in!the!population!description!
8!patients!with!no!follow!up!at!one!year!!
14!patients!explanted!or!deceased!in!the!first!year!after!kidney!transplantation!
110!patients!transplanted!before!01.01.08!excluded!for!2!reasons:!Lack!of!BK!viremia!followIup!and!UreteralI!stent!extremely!unusual!!
3!patients!without!known!removal!date!of!ureteral!stent!!195!patients!for!detailed!statistical!analysis!
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Prophylaxis of infections: Patients received valgancyclovir (Valcyte) as 
cytomegalovirus (CMV) prophylaxis during 3 to 6 month according to the 
donor/recipient (D/R) serostatus. As the glomerular filtration rate (GFR) is often 
<60ml/min/1.73m2 after kidney transplantation, the dose was adjusted to it. The 
patients whose CMV serostatus was D-/R- received valacyclovir (Valtrex) instead as 
prophylaxis against herpes simplex virus (HSV). All patients were also under 
antibacterial prophylaxis with co-trimoxazole (trimethoprime-sulfamethoxazole, 
Bactrim Forte) during 6 months, and prophylaxis against mucosal mycosis by 
nystatine (Mycostatine) for the first 2 weeks after transplantation. 
 
BK viremia screening: All patients have been regularly screened for BK virus within 
the first year after transplantation (at 3-6-12 months or 2-4-6-12 months, as per 
protocol) since 2008. Unless a positive history of BK viremia, no screening (viremia, 
D/R serology) was performed prior to transplantation. BK virus DNA detection in the 
patient’s serum was performed using quantitative polymerase chain reaction (PCR). 
The serum samples were analysed in Basel until 30.06.2008, thereafter at the CHUV. 
No significant difference has been found between the analyses performed in the two 
different institutions.  
For our study, patients had to have at least two consecutive serum samples with BK 
viremia >1’000 copies/ml to be considered as BK viremia positive. BKVN was defined 
either by typical histological features on graft biopsies or in the setting of persistent 
high viremia (>10’000 copies/ml twice). 
There are currently no approved guidelines to treat BK viremia/nephropathy. 
According to CHUV’s protocols, immunosuppression was reduced, starting with the 
dosage of anti-metabolites together with reduced trough levels of FK. If insufficient, 
anti-metabolites were completely stopped and FK switched to CsA, while steroids 
were maintained. In some instances, IvIg was used (1 cycle of 3 days for a total dose 
of 2g/kg weight; in some patients repeated at 1 month interval). 
 
Statistical analysis: Data were gathered in a Microsoft Office Excel database, 
before being simplified and grouped into categories. In a first phase, descriptive 
statistics were performed using all the patients who were included in the study, in 
order to define general characteristics of the population transplanted and regularly 
followed at the CHUV. We then analyzed and compared patients based on their BK 
status and the presence/absence of a ureteral stent.  
Statistical analyses were performed using R-software, with the help of Dr I. Salvade. 
Continuous data were expressed using mean values (standard deviation) and 
categorical data were described as numbers (percentages). Categorical data 
including demographic, clinical events (ureteral stent), immunosuppressive drugs and 
BK-related events were compared using Fisher's exact test. Associations between 
the presence of a ureteral stent as well as other risk factors and the occurrence of BK 
viremia was explored by univariate and multivariate analysis. A p-value of <0.05 was 
considered as statistically significant.  
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Results and discussion 
1.    Donors and recipients characteristics  
Table 1. Description of the study population  
 Total population           2003-2012 (n=308) 
Subpopulation  
2008-2012 (n=195) 
 n % n % 
Gender F / M 92/216 29.9/71.1 55/140 28.2/71.8 
Mean age (years) 51.7  52.9  
First / prior Tx 239/69 77.6/22.4 152/43 77.9/22.1 
Living / cadaveric donor 151/157 49.0/51.0 101/94 51.8/48.2 
 
Table 1 shows in parallel the characteristics of the 308 patients transplanted with a 
kidney at the CHUV between November 2003 and December 2012, as well as of the 
subpopulation of 195 patients transplanted between 2008 and 2012 that we analysed 
in more detail for BK viremia. There was no significant difference in gender 
distribution, mean age at transplantation, type of donor and immunological risk of the 
recipient (low i.e. first graft vs. high immunological risk i.e. more than 1 
transplantation) between the 2 groups. This reflected a similar starting population at 
transplantation in the two periods. Regarding post-transplant management, BK 
viremia screening was introduced systematically only in the newest era. 
About 71% of the transplanted patients were men, a proportion that can also be 
found in other studies about kidney transplantation (2)(3). As we only analysed the 
adult population, the age range extended from 21 to 79 years, with a mean age of 52 
years. Around 22% of the population had already received a prior transplant (kidney, 
heart, liver or lungs) and was therefore considered at high immunological risk. This is 
important information as the immunological risk of the recipient dictates the intensity 
of the induction and maintenance immunosuppressive therapy after transplantation. 
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2.  Immunosuppression 
Table 2. Immunosuppression 
  Total population 2003-
2012 (n=308) 
Subpopulation        
2008-2012 (n=195) 
n % n % 
Induction 
Basiliximab  210 68.2% 134 68.7% 
Basiliximab + 
Thymoglobulin 38 12.3 27 13.8 
Thymoglobulin     
(3-4 days) 38 12.3 17 8.7 
Thymoglobulin     
>4 days 8 2.6 6 3.1 
Thymoglobulin + 
IvIg 14 4.5 11 5.6 
Maintenance 
FK / CsA 295/13 95.8/4.2 187/8 95.9/4.1 
MMF / AZA 294/14 95.5/4.5 185/10 94.9/5.1 
FK + MMF + P 281 91.2% 177 90.8% 
Other associations 27 8.8 18 9.2 
Treatment at 
one year 
FK / CsA / mTORi 282/21/5 91.6/6.8/1.6 180/13/2 92.3/6.7/1.0 
MMF / AZA / None 262/25/ 21 85.1/8.1/6.8 165/17/ 13 84.6/8.7/6.7 
FK + MMF ± P 242 78.6% 153 78.5% 
Other associations 66 21.4 42 21.5 
 
Table 2 shows that at the time of transplantation, the standard immunosuppression 
treatment consisted mainly of Basiliximab-based induction followed by the 
association of FK, MMF and Prednisone as maintenance therapy. Basiliximab 
induction therapy (2 doses, day 0 and 4) was given to low immunological risk patients 
(first transplantation, non-sensitized), whereas the high immunological risk patients (≥ 
2 transplantations, prior HLA immunization) received Thymoglobulin instead. In case 
of delayed graft function (DGF), Thymoglobulin was added to Basiliximab given on 
day 0, or Thymoglobulin treatment was prolonged (>4 days) in order to delay the 
introduction of potentially nephrotoxic CNI (FK or CsA), until the recovery of acute 
tubular necrosis and renal function. About 5% of the recipients were hypersensitized 
with pre-existing donor-specific antibodies (DSA). These patients received 
Thymoglobulin induction and IvIg to prevent antibody-mediated graft rejection.  
The maintenance therapy was initiated during the first days after transplantation 
and was mainly (>90%) based on the association of FK, MMF and Prednisone (P). 
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This protocol was relatively standardized and stable during both study periods, 
(whole period 2003-2012, and subpopulation studied between 2008-2012 for BK 
events). For about 4% of the population, CsA has been preferred to FK due to the 
risk of post-transplantation diabetes, chronic HCV or depending on the underlying 
nephropathy (for example in the case of primary focal segmental glomerulosclerosis). 
For another average 4.5% of the population, MPA-based agents (Cellcept® or 
Myfortic®) were switched to AZA in the early post-transplant period, mainly because 
of gastrointestinal side effects. 
The IS therapy at 1 year after transplantation, which often reflects the immunological 
and infectious events that had occurred during the year, was still mainly represented 
by the association of FK, MMF ± Prednisone (78%). As compared to the early IS 
maintenance therapy, the percentage of patients under CsA (vs. FK) or AZA (vs. 
MPA-based agents) was slightly increased. In less than 2% of patients, mTORi were 
used, usually to replace CNI in case of severe nephrotoxicity and/or thrombotic 
microangiopathy. Some patients were on CNI (either FK or CsA) and Prednisone, but 
received no anti-metabolites (MMF or AZA). This was usually the case if patients had 
high levels of BK viremia and/or BKVN during the first year. Prednisone was tapered 
progressively during the first year and sometimes stopped before month 12 after 
transplantation, usually leaving patients under FK and MMF therapy. 
 
3.   Kidney transplantation characteristics 
Table 3. Kidney transplantation  
 Total  Living donors Cadaveric donors 
n n % n % 
End 2003+2004 29 11 37.9 18 62.1 
2005 29 14 48.3 15 51.7 
2006 24 10 41.7 14 58.3 
2007 28 12 42.9 16 57.1 
2008 38 24 63.2 14 16.8 
2009 37 17 45.9 20 54.1 
2010 45 22 48.9 23 51.1 
2011 32 19 59.4 13 40.6 
2012 46 22 47.8 24 52.2 
Total 308* 151 49.0% 157 51.0% 
 
*14 patients explanted or deceased in the first year post-transplantation and 8 with no follow-up at one 
year are not represented in this table.  
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Graph 1. Kidney transplantations performed at CHUV 
	  
As shown in Table 3 and Graph 1, the number of renal transplantations performed at 
the CHUV has increased through the study period (about +50% in 9 years). On 
average, the proportion of living donors has also increased, with some variations 
according to the years. Because of the aging of the population and the progresses in 
medical and surgical management of patients suffering from chronic kidney diseases, 
more patients are becoming suitable candidates for transplantation, extending the 
waiting list. However, the number of cadaveric donors remains insufficient. The 
increasing awareness of the possibility of kidney donation by a relative or 
partner/friend together with progresses in minimal invasive surgical techniques for 
kidney removal have increased the proportion of living donation in recent years. But 
the gap between the number of patients on the waiting list and kidney 
transplantations performed every year is still growing. In 2014, according to Swiss 
Transplant statistics, 1062 patients were waiting for a kidney while a total of 296 have 
been transplanted in Switzerland (https://www.swisstransplant.org). 
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4. Surgical use of ureteral stents at the time of kidney transplantation 
 
Table 4. Description of the use of ureteral stents 
Total patients transplanted between 01.01.08 and 31.12.12 (n=195) 
 n % 
Stent / no stent 76 / 119 39% / 61% 
Causes of stent placement (n=76) 
Ureter  18 23.7% 
Short/fine ureter 15  
Double ureter system 3  
Vascular 14 18.4% 
Inferior polar artery 9  
Devascularized ureter or with little adjacent fat 5  
Bladder  5 6.6% 
Micro-bladder (anuric or post radiotherapy) 3  
Anastomosis to an ileal bladder (Bricker) 2  
Anastomosis 8 10.5% 
Unsatisfactory surgical anastomosis 2  
Ureteral leak 1  
Stenosis 5  
No specific cause reported  31 40.8% 
Causes of stent ablation (n=76) 
Per protocol (no problem reported) 57 75.0% 
Infection 9 11.8% 
Discomfort/intolerance/displacement 7 9.2% 
Hematuria (micro/macro) 2 2.6% 
Obstruction 1 1.3% 
Time interval between stent placement and ablation (n=76) 
<1 month (<30 days)  19 25.0% 
1-2 months (31-60 days) 39 51.3% 
2-3 months (61-90 days) 13 17.1% 
>3 months (>90 days) 5 6.6% 
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To analyse the potential effect of a ureteral stent on the incidence of BK viremia after 
kidney transplantation, the surgery protocols were reviewed and all information about 
ureteral stents were recorded. From the 195 patients transplanted between 01.01.08 
and 31.12.12, a ureteral stent was used in 76 cases (39%). At our institution, during 
the study period, the decision to place a ureteral stent was made by the transplant 
surgeon at the time of transplantation.  
We analysed the reasons of stent placement and classified them into 5 categories 
(Table 4). Eighteen (23.7%) stents have been placed because of ureteral problems 
(short/fine ureter or double ureter system). Inferior polar artery, devascularized ureter 
or little remaining adjacent fat were reported as the cause of 14 stents placements 
(18.4%). Five stents (6.6%) were placed because of a specific bladder anatomy 
(micro-bladder or ileal bladder). Complications of the anastomosis at the time of 
transplantation, an unsatisfactory surgical anastomosis and subsequent early 
ureteral leak or stenosis resulted in 8 stents (10.5%). For the other 40% of ureteral 
stent placement, no reason was reported in the operative protocol and these stents 
have probably been placed according to the surgeon’s preference. 
Regarding stent ablation, 75% of them have been removed per protocol, while no 
problem was reported. Nine stents (11.8%) have been taken out because of urinary 
tract infection, seven (9.2%) because of discomfort, intolerance or displacement of 
the stent, two (2.6%) because of haematuria and one (1.3%) following an obstruction. 
While most ureteral stents have been used without complication, our analysis 
illustrates that it is however not an insignificant procedure as reflected by 24.9% of 
the patients that have suffered from complications. Furthermore, the removal of 
ureteral stents requires an additional urological procedure, which can be 
uncomfortable for the patient.  
According to our protocol, ureteral stents had to be removed between 4 to 6 weeks 
post transplantation. That was the case for more than 50% of the patients and in this 
group only 4/39 stents were removed following a complication. Nineteen stents (25%) 
were removed before 4 weeks and for 2/3 of them (12/19) an early complication was 
reported. Thirteen stents (17.1%) stayed in place an extra month and 5 (6.6%) more 
than 3 months. In these two last groups, only 3 episodes of urinary tract infections 
were reported as a complication. Among the 5 stents that stayed more than 3 
months, 3 had been placed subsequent to an anastomosis stenosis. Of note, 1/5 of 
these latter patients presented transient (<1 month) early BK viremia overlapping the 
stenting period, but resolution of viremia occurred without the need of stent removal. 
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5.  Incidence of BK viremia after kidney transplantation  
Table 5. Description of BK viremia   
Total patients transplanted between 01.01.08 and 
31.12.12 (n=195)   
 n % 
BK viremia/  
no BK viremia 43/152 22/78 
BK viremia in the 1st year 
post-transplantation 37 
19% 
Peak BK virus copies/ml in plasma PCR                                   
(within the first year post Tx) (n=37) 
1’000-10’000 9 24.3 
10’000-100’000 20 54.1 
>100’000 8 21.6 
Time distribution BK viremia onset (n=43) BK viremia peak (n=43) 
1st month: 1-30 days 0 0 0 0 
2nd month: 30-60 days 5 11.6 1 2.3 
3rd month: 60-90 days 11 25.6% 4 9.3 
4th month: 90-120 days 12 27.9% 18 41.9% 
5th month: 120-150 days 4 9.3 5 11.6 
6th month: 150-180 days 3 7.0 5 11.6 
7-12th month: 180-365 days 2 4.6 4 9.3 
> 365 days 6 14.0 6 14.0 
Time interval between  Onset and peak of viremia (n=43) 
Onset and resolution of 
viremia (n=43) 
0 days                       
(beginning value=peak) 12 27.9 - - 
1-30 days 22 51.2% 3 7.0 
30-60 days 7 16.3 15 34.9% 
60-90 days 2 4.6 8 18.6 
90-180 days 0 0 6 14.0 
180-365 days 0 0 5 11.6 
> 365 days 0 0 6 14.0 
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Of the 195 patients transplanted between 01.01.08 and 31.12.12, BK viremia >1’000 
DNA copies/ml was found in 43 patients (22%), of which 37 (19%) within the first year 
after transplantation (Table 5). When looking at the time distribution of BK viremia 
onset, most events occurred during the 3rd (60-90 days) and 4th (90-120 days) month 
after transplantation, respectively 25.6% and 27.9%. No BK viremia was detected 
during the first month, probably reflecting very rare screening performed during this 
early period. Only 2 cases (4.6%) were diagnosed between months 7 and 12  
The time distribution of BK viremia onset (>1’000 copies/ml) and peak values that we 
observed in our study tends to reinforce the current screening strategy performed at 
the CHUV, i.e. at month 2, 4, 6 and 12 after transplantation, independent of kidney 
function. Extra testing at month 3 might be proposed as 25.6% of BK viremia started 
at that time. Interestingly, 14% of BK viremia cases were newly diagnosed after 12 
months: 5/6 during the second year post transplantation and 1/6 during the third year. 
The KDIGO guidelines report that 95% of BKVN occur in the first 2 years after kidney 
transplantation (16). Beyond the first year after transplantation, there is no clear 
guidelines regarding whether and at which frequency screening should be performed 
in the absence of previous BK viremia. The current clinical practice at the CHUV is to 
perform screening in the case of kidney dysfunction and/or intensification of the 
immunosuppressive regimen.  
We defined the peak of BK viremia as the highest values of copies/ml measured in a 
patient during the 1st year follow-up. More than 50% peak values happened during 
the first month after onset of BK viremia and 16.3% during the second month. This 
may reflect rapid replication of the virus in peripheral blood after onset, and the need 
for rapid and early detection to prevent BKVN. For 27.9% of recipients, their first BK 
viremia result was already the peak value. Prompt management with reduction of 
immunosuppression probably accounts for the rapid decrease of BK viremia that we 
observed after the first detection. As the incidence of BKVN has been linked to the 
extent of BK viremia, we stratified peak values within the first year into 3 categories: 
1’000 to 10’000 copies, 10’000 to 100’000 copies and >100’000 copies, with 24.3%, 
54.1% and 21.6% of the patients in the respective groups. Among the 37 patients 
with positive BK viremia during the first year after transplantation, 28 (75.7%) had 
peaks >10’000 copies, a cut-off value considered as predictive of intragraft viral 
replication resulting in tubulointerstitial damage. To put our data into perspective, 
Kayler et al. (2) reported 93/600 (15.5%) BK viremia (defined in their study as >500 
copies/ml) within the first post-transplant year and in 70 of these cases (75.3%), the 
peak BK PCR level was >10’000 copies/ml. In our studied transplanted population, 
28 out of total 195 patients (14.4%) had a peak BK viremia >10’000 copies which 
represents a high positive predictive value for BKVN (KDIGO)(16). In our centre, we 
did not systematically perform kidney biopsies to confirm the diagnosis of BKVN in 
these patients, but IS was modified in all cases as if they had BKVN. As a 
comparison, the incidence of BKVN reported in the literature is much lower (2-5%) 
(17). 
Resolution was defined as the date BK viremia reached a value <1’000 copies/ml, in 
the absence of further increase in later follow-ups. One third of the patients cleared 
the virus between 30 and 60 days after the onset of viremia and at 6 months, 74.5% 
of the patients had reached a value <1’000 copies. The remaining patients that 
displayed persisting viremia (>one year) had all reached a peak value >10’000 
copies/ml, some of them even >100’000 copies/ml. 
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Diagram 2. Distribution of BK viremia 
The following diagram summarises our findings regarding BK viremia incidence. 
 
 
 
 
6.  Effect of BK viremia on kidney function at one year 
We considered kidney function at one year as one of the outcomes of this study as it 
would, at least in part, reflect the severity of BKVN in the presence of BK viremia. 
Kidney function at 1 year after transplantation was also shown to be a good predictor 
of future graft and patient survival. The glomerular filtration rate was calculated 
(eGFR) using the Cockroft and Gault formula, with patient data collected at one year 
(weight, serum creatinine, sex and age). Of note, the Cockroft and Gault formula has 
been developed for chronic kidney disease (CKD) patients and may not be accurate 
in the setting of renal transplantation. However, other available formulas (MDRD, 
CDK-EPI, Nankivell) that are used in CKD patients have also not been validated to 
estimate GFR after kidney transplantation.  
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Table 6a. Kidney function at 1 year  
 eGFR (ml/min) 
Mean kidney function (n=195) 65 
Patients with no BK viremia (n=158, 81%) 67 
Patients with BK viremia (n=37, 19%) 58 
BK viremia 1’000-10’000 copies/ml (n=9) 65 
BK viremia 10’000-100’000 copies/ml (n=20) 61 
BK viremia >100’000 copies/ml (n=8) 44 
The mean eGFR at 1 year after kidney transplantation was 65 ml/min, which 
corresponds to CKD stage II (Tables 6a and 6b). In our population of 195 kidney 
transplant recipients, we found a significant difference (p=0.019) between the two 
groups (no BK viremia vs. BK viremia during the first year post transplantation). The 
eGFR decreased as BK viremia levels increased, in particular above 10’000 
copies/ml, which could be explained by potential BKVN and associated renal 
damages. 
Table 6b. Kidney function 
CKD 
stage eGFR (ml/min) 
No BK viremia 
(n=158) 
BK viremia (copies/ml) (n=37) 
1’000-10’000 10’000-100’000 >100’000 
I ≥ 90 15 (9.5%) 1 0 0 
II 60-89 82 (51.9%) 4 12 1 
III 30-59 58 (36.7%) 4 8 5 
IV 15-29 3 (1.9%) 0 0 2 
V < 15 0 0 0 0 
  
 
7.  Predictive factors for BK viremia after kidney transplantation 
As described before, the population analyzed in our study was demographically 
representative of current adult kidney transplant recipients followed in most centers, 
with a mean age of 52.9 years (range 21-79). Of note, 71.8% of our patients were 
men. We first performed univariate analysis to determine the association between the 
use of a ureteral stent at the time of initial surgery and BK viremia. The Fisher’s 
Exact Test did not show a significant association (p=0,38). This result should 
however be interpreted with caution as we had relatively few events: 43 BK viremia in 
the population studied (22%) and only 76 out of the total 195 patients (39%) had a 
ureteral stent. Other studies have shown an association between the use of an 
ureteral stent and the occurrence of BK viremia (2)(3)(4)(5)(8). As for our study, 
these were all retrospective and single-center studies, with the number of patients 
ranging from 66 to 621 (Table 7). However, the rate of ureteral stents was not 
comparable between centers (probably reflecting local surgical protocols), as well as 
the definitions of BK-related outcomes (levels of viremia, occurrence of BKVN). 
23 
 
Therefore, to determine whether the use of a ureteral stent at the time of surgery is 
an independent risk factor for BK viremia in kidney transplant recipients, prospective 
randomized studies with careful analysis of concomitant variables 
(immunosuppression protocols, initial surgical protocols, urological complications 
during the first year, etc.) are needed.  
Table 7. Comparison with available literature 
Author, Year 
Type of study 
Total 
patients 
(n) 
Ureteral 
Stent 
n (%) 
BK 
viremia 
n (%) 
 Inferior 
limit of 
viremia 
p-value OR 
Brennan, 2005 
Retrospective 200 54 (25%) 
23 
(11.5%) 
10’000 
copies/ml 0.018 HR = 3.0 
Thomas, 2007 
Retrospective 66 31 (47%) 
2% 
BKVN 
BKVN 
(biopsy) 0.003 
Univariate 5.6      
Multi 4.71 
Siparsky, 2011 
Retrospective 186 
124 
(67%) 
32 
(17%) 
2.7 log 
copies/ml 0.02 3.17 
Kayler, 2012 
Retrospective 600 
295 
(49.2%) 
93 
(15.5%) 
500 
copies/ml 
Uni 0.06 
Multi 0.03 
Uni 1.53 
Multi 1.65 
Hashim, 2014 
Retrospective 621 
295 
(47.5%) 
115 
(19.0%) 
500 
copies/ml 
Uni 0.05        
Multi 0.04 1.55 
Our study, 2015 
Retrospective 195 76 (39%) 
43 
(22%) 
1000 
copies/ml 0.38  
In our routine practice, we had noticed the occurrence of BK viremia in patients 
presenting urological complications in the first year after transplantation, such as 
benign prostatic hyperplasia, urethral stenosis, urinary retention and 
ureteroneocystostomy leakage, which required urological manipulations after initial 
transplantation surgery (vesical catheter, transurethral resection of the prostate, 
ureteral stent or nephrostomy). As this study was retrospective based on medical 
charts and electronic files, the quality of the data was not sufficient to study the 
association between post-operative urological complications and BK viremia. This 
could be best verified in a prospective study, as previously mentioned. 
The hypothesis of urothelium injury as a necessary determinant for the 
development of a BKVN has been made by Atencio et al. (18) who proposed a two-
hit hypothesis, also reported by Thomas et al. (5). The first hit corresponds to the 
reactivation of BK virus from latency in the setting of immunosuppression. The 
second hit, which appears to be necessary for de progression of BKVN, is renal cell 
injury. This is supported by the fact that in murine models, BK virus reactivation could 
be induced by various chemical and mechanical insults, such as renal artery 
clamping to produce renal ischemia. This theory could partially explain why BKVN is 
more frequent in kidney transplant recipients as compared to other 
immunosuppressed patients. The renal cell insult produced by ischemia-reperfusion 
and/or rejection episodes in the context of immunosuppression may provide the 
necessary environment for BK virus replication. In addition, in animal models, ureteral 
stents have been shown to cause superficial epithelial destruction with erosions, 
ulcerations and inflammatory reactive changes. Thomas et al. (5) postulated that 
similar reactive urothelial changes could be expected to occur in the donor ureter 
secondary to the placement of a stent, which may result in BK virus reactivation and 
replication. 
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As potent immunosuppression is a known risk factor for BK viremia, we then 
analyzed the role of IS therapy on BK-related events in our transplanted population. 
Neither differences in the induction (Thymoglobulin vs. Basiliximab) nor in the 
maintenance therapy (FK vs. CsA) were significant determinants for BK viremia. 
According to literature, Thymoglobulin, the T-cell depleting agent, increases the risk 
of BK infection, whereas Basiliximab, the reversible T-cell modulator, does not. FK is 
known as a major risk factor for BK viremia as it inhibits BKV-specific T cells while 
CsA has been shown to suppress viral replication in vitro. In our population, 
maintenance protocols were very homogeneous and therefore too little patients were 
receiving CsA for a statistically relevant comparison. In our study, where >95% of the 
patients initially received FK and >90% were prescribed FK+MMF+P maintenance 
therapy early after transplantation, it would have been more informative to compare 
FK trough levels over time and possible associations with BK viremia. Indeed, the 
though level, rather than the dosage, represents the global biological effects of IS. It 
was unfortunately not part of our initial data collection and would have implied 
statistical analysis beyond the scope of this retrospective study. In recent years, with 
the improvement of rejection management and the awareness of BKVN among other 
complications, guidelines have recommended lower target levels of IS. To some 
extent, the CHUV patients have been managed according to these 
recommendations, which could in part explain lower incidences of high titer BK 
viremia (>10’000 copies/ml) and BKVN. 
Since ischemia-reperfusion is known to cause initial graft damage, we compared 
BK viremia in kidney transplant recipients of living vs. cadaveric donors. In our 
population of patients transplanted between 2008 and 2012, the two groups were 
comparable in size, with 101 (51.8%) and 94 (48.2%) grafts from living and cadaveric 
donors, respectively. We found no significant association between the type of graft 
and BK viremia. Some studies mention prolonged ischemia time as a risk factor for 
BK viremia. Compared to the USA, Switzerland is a small country and cold ischemia 
time is usually much shorter (living donors: 42min-4h, cadaveric donors: mean 
10h15, range 4h30-19h30). 
 
Figure 2. Probability of BK viremia, according  
to age and gender (F, red line; M, blue line).	   	  
Concerning the demographic 
characteristics of our population, 
recipient’s age and sex, analyzed 
separately, were no predictive factors 
for BK viremia. But by combining 
these two variables, we observed that 
the probability for a man to suffer from 
BK viremia increased with age, with a 
p-value reaching significance 
(p=0.05) (Figure 2). In comparison, 
the risk did not increase with age in 
women. As mentioned before, 
urological complications, which are 
more frequent in older men, could be 
a contributing factor for BK virus 
replication. 
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Conclusion and perspectives 
In the past 20 years, BK virus has emerged as a cause of graft dysfunction after 
kidney transplantation, leading to specific measures in the post-transplantation 
management. Indeed, the importance of early detection of BK viremia in plasma by 
DNA PCR in order to adapt IS and prevent BKVN is now widely acknowledged (16). 
So far, besides the amount and type of IS, little has been published on other risk 
factors and current data are controversial.  
The first aim of our study was to define the incidence and kinetics of BK viremia in 
our recipients of kidney grafts during the first year. Among the 195 patients 
transplanted at the CHUV between 01.01.2008 and 31.12.2012, 37 (19%) presented 
a BK viremia >1’000 copies/ml, which is comparable to published data (2)(3)(4). In 
most cases, the onset of BK viremia occurred early after transplantation. In 65.1% of 
the cases, positive BK viremia was detected during the first 4 months (defined in our 
study as BK viremia >1’000 copies/ml in at least two consecutive serum samples), 
with a peak viremia value at 30 days following onset in 51.2%. Interestingly, 6 
patients were newly diagnosed after 12 months of transplantation. Prompt 
management with reduction of IS was generally set up in order to reduce viral loads 
and to protect the graft. To assess the consequences of BK viremia, we analysed 
kidney function at one year and observed a significant difference (9 ml/min, p=0.019) 
between the mean eGFR of patients with no BK viremia (eGFR 67 ml/min) and 
patients with BK viremia (eGFR 58 ml/min). The eGFR decreased as BK viremia 
levels increased, possibly reflecting BKVN-associated damages.  
Considering the total incidence of BK viremia in our population (22%), the fact that 
BKVN is a factor of poor prognosis for graft function and that viremia detection by 
PCR allows early diagnosis and management, our data reinforce the importance of 
regular screening after kidney transplantation. The KDIGO guidelines (16) propose a 
monthly screening schedule for the first 3-6 months after transplantation, then every 
3 months until the end of the first post-transplant year, as well as whenever there is 
an unexplained rise in serum creatinine and after treatment for acute rejection. We 
could propose adding to the current CHUV protocol (PCR at 2-4-6-12 months then 
1x/year) extra testing at 3 and 5 months and after 12 months in the presence of an 
unexplained rise in serum creatinine.  
In order to identify the population at risk for BK virus reactivation and to propose a 
more individualised follow-up, in particular regarding screening and the degree of IS, 
we analysed potential factors and their association with the occurrence of BK viremia 
in our population. We found no significant association with the type of graft (living vs. 
cadaveric donor), or with the IS protocol (Basiliximab vs. Thymoglobuline, FK vs. 
CsA). However, by combining recipient’s age and gender, it appeared that older men 
had a higher risk to reactivate the BK virus, with a p-value reaching significance 
(p=0.05). This finding needs to be confirmed in further studies with a special attention 
to urological complications and manipulations, which could not be analysed in detail 
in our retrospective study. 
The placing of a ureteral stent has been mentioned in the literature as a potential risk 
factor for BK viremia (2)(3)(4)(5)(8). In our transplanted population, we reported the 
use of ureteral stents in 76/195 patients (39%). The decision was made by the 
transplant surgeon, according to the ureter and bladder anatomy or due to 
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unsatisfactory vascularisation or anastomosis complications. In our study, we found 
no significant association between the use of a ureteral stent and BK viremia.  
Overall, this study is limited by its design as a retrospective single-centre cohort 
analysis, based on medical paper charts and electronic files in which not all outcome 
data were strictly reported (for instance, urological complications). Although we 
initially aimed to include all transplanted patients from end of 2003 onwards (n=308), 
the study was finally restricted to a more recent era (2008 onwards, n=195) when BK 
viremia screening protocols were applied at CHUV as well as more frequent use of 
ureteral stents. Moreover, in recent years in our centre, BKVN was an assumed 
diagnosis in the setting of persistent high BK viremia i.e. >10’000 copies/ml at least 
twice, a cut-off value considered as predictive of intragraft viral replication and 
tubulointerstitial damage. Thus, kidney biopsies were not systematically performed to 
confirm the diagnosis and evaluate the severity of nephropathy.  
BK virus, first detected in 1971 and considered as a cause of kidney graft dysfunction 
since 1995, remains a fascinating entity with lots of remaining unanswered questions. 
The aetiology of BK replication and BKVN, which seems to be multifactorial, has to 
be better defined in order to optimise the follow-up of kidney transplant recipients. So 
far, in the absence of proven polyomavirus-specific antiviral agents, the mainstay of 
BK viremia/BKVN management remains the reduction of IS, which has to be carefully 
monitored to avoid acute and chronic rejection. The early detection of BK viremia 
prior to graft damage appears nowadays as the best clinical option to improve graft 
outcome after kidney transplantation. The advent of specific anti-viral therapies or of 
more standardised protocols aiming at reducing IS in the case of BK viremia would 
further help the clinician minimize early graft dysfunction and loss. 
Based on current knowledge and on our data, we could suggest performing a 
prospective randomized multicenter study with controlled cofactors 
(immunosuppression, surgical use or not of ureteral stents) and detailed follow-up 
charts (including urological complications/manipulations) to better analyse the 
determinants of BK viremia and BKVN. Interestingly, in Switzerland some 
transplantation centers (Geneva, Bern, Zurich) use systematically ureteral stents at 
the time of transplantation surgery. It would be interesting to analyse BK viremia 
rates during the first year in these different centers and to compare the data with our 
study. In this regard, the data gathered prospectively since 2008 in the multicenter 
Swiss Transplant Cohort Study (STCS) could help answer these questions. 
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